ANL 28.06 Decreased By ▼ -0.11 (-0.39%)
ASC 16.62 Decreased By ▼ -0.14 (-0.84%)
ASL 23.94 Decreased By ▼ -0.01 (-0.04%)
AVN 91.13 Decreased By ▼ -0.53 (-0.58%)
BOP 9.68 Decreased By ▼ -0.03 (-0.31%)
BYCO 9.90 Decreased By ▼ -0.03 (-0.3%)
DGKC 113.68 Increased By ▲ 0.18 (0.16%)
EPCL 48.84 Decreased By ▼ -0.77 (-1.55%)
FCCL 21.81 Increased By ▲ 0.15 (0.69%)
FFBL 27.53 Decreased By ▼ -0.17 (-0.61%)
FFL 18.13 Increased By ▲ 0.14 (0.78%)
HASCOL 14.82 No Change ▼ 0.00 (0%)
HUBC 86.28 Decreased By ▼ -0.18 (-0.21%)
HUMNL 7.40 Increased By ▲ 0.05 (0.68%)
JSCL 29.41 Decreased By ▼ -0.19 (-0.64%)
KAPCO 38.39 Increased By ▲ 0.08 (0.21%)
KEL 4.21 Decreased By ▼ -0.03 (-0.71%)
LOTCHEM 16.00 Increased By ▲ 0.04 (0.25%)
MLCF 43.44 Decreased By ▼ -0.11 (-0.25%)
PAEL 40.49 Decreased By ▼ -0.11 (-0.27%)
PIBTL 13.04 Increased By ▲ 0.04 (0.31%)
POWER 11.74 Decreased By ▼ -0.04 (-0.34%)
PPL 97.93 Increased By ▲ 0.48 (0.49%)
PRL 25.43 Decreased By ▼ -0.05 (-0.2%)
PTC 9.78 No Change ▼ 0.00 (0%)
SILK 1.21 No Change ▼ 0.00 (0%)
SNGP 46.50 Increased By ▲ 0.01 (0.02%)
TRG 97.18 Decreased By ▼ -0.20 (-0.21%)
UNITY 31.70 Increased By ▲ 0.12 (0.38%)
WTL 1.15 Decreased By ▼ -0.03 (-2.54%)
BR100 4,856 Decreased By ▼ -11.74 (-0.24%)
BR30 24,507 Decreased By ▼ -1.43 (-0.01%)
KSE100 45,931 Decreased By ▼ -58.35 (-0.13%)
KSE30 19,110 Decreased By ▼ -68.04 (-0.35%)
World

China's Sinovac COVID-19 vaccine appears safe in last stage trials: Researchers

  • Butantan Institute states CoronaVac proved to be safe in a trial so far involving 9,000 volunteers
Updated 20 Oct 2020

(Karachi) In a last stage clinical trial, an experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe, preliminary results showed.

Brazil's leading bio-medical research centre Butantan Institute engaged in carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

But the research institute's director Dimas Covas said that results of the data on vaccine's effectiveness will not be released till completion of the trial. The trial is being conducted on 13,000 volunteers.

He stated that researchers will keep monitoring the participants in the on-going trial. He mentioned there were no severe adverse reactions to the vaccine, with 20% of the volunteers reporting mild pain

It's the first set of results of Sinovac's Phase 3 global trials, which are also being conducted in Turkey and Indonesia.

Earlier, the China-based biopharmaceutical company Sinovac Biotech started Phase III clinical trial of its inactivated Covid-19 vaccine in Turkey. The company has already performed Phase I/II studies of the vaccine in volunteers aged 18 to 59 years and those aged 60 years old and above, at Jiangsu and Hebei Provinces on April 16 and May 22, respectively, in China.